Lipoprotein-associated Phospholipase A2 (Lp-PLA2) test is repatriated to Eurofins Biomnis
From the 19th of February 2024, we will be changing the referral laboratory for lipoprotein-associated phospholipase A2 (Lp-PLA2) from The Doctors Laboratory (TDL) in London to our sister laboratory Eurofins Biomnis France. As a result of this change, reference ranges will change as follows:
- OLD REFERENCE RANGE: < 560 U/L
< 560 U/L: low risk
560 – 619: intermediate risk
620 – 634: borderline risk
≥ 635: high risk
- NEW REFERENCE RANGE: < 200 ng/mL
Reference values according to Lp-PLA2 supplier data on 256 self-reported healthy individuals:
<200 ng/ml (90th percentile)
<250 ng/ml (95th percentile)
This specifically vascular marker is not influenced by systemic inflammation (infections, obesity, smoking), unlike hs-CRP. Elevation of Lp-PLA2 levels is therefore independent of other risk factors such as obesity, metabolic syndrome, hypertension and diabetes; when compared with oxidized LDL levels, it can help predict the existence and, above all, the fragility of potential atherosclerotic plaque.
The move will benefit our clients in every singe sense, including shorter turnaround times and best cost-effectiveness.
